A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Zanubrutinib (BRUKINSA)

Zanubrutinib targets specific kinase enzymes involved in cancer cell growth and proliferation.

First FDA approval2019-11-14
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$2.91B in CY2024 Part D spend219K claims · 37K beneficiaries · 329 plans surveyed

Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
327 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Zanubrutinib used for?

Zanubrutinib targets specific kinase enzymes involved in cancer cell growth and proliferation.

Is there a generic for Zanubrutinib?

No. Zanubrutinib is brand-only with no generic equivalents currently in market.

How much does my plan pay for Zanubrutinib?

NADAC pricing data not currently available for this drug.

Is Zanubrutinib on the FDA shortage list?

No. Zanubrutinib is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (1 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.